Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Oral magnesium supplementation in insulin-requiring Type 2 diabetic patients. Effect of oral magnesium supplementation on selected cardiovascular risk factors in non-insulin-dependent diabetics. Improved Insulin Response and Action by Chronic Magnesium Administration in Aged NIDDM Subjects The Effect of Magnesium Supplementation in Increasing Doses on the Control of Type 2 Diabetes Changes in glucose turnover parameters and improvement of glucose oxidation after 4-week magnesium administration in elderly noninsulin-dependent (type II) diabetic patients. Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial. Effects of oral magnesium supplementation on insulin sensitivity and blood pressure in normo-magnesemic nondiabetic overweight Korean adults. Magnesium intake decreases Type 2 diabetes risk through the improvement of insulin resistance and inflammation: the Hisayama Study. Oral magnesium supplementation in type II diabetic patients Effects of oral magnesium supplementation on plasma lipid concentrations in patients with non-insulin-dependent diabetes mellitus. Magnesium improves the beta-cell function to compensate variation of insulin sensitivity: double-blind, randomized clinical trial. Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial. Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Daily magnesium supplements improve glucose handling in elderly subjects. Magnesium and ascorbic acid supplementation in diabetes mellitus. Lower intake of magnesium and dietary fiber increases the incidence of type 2 diabetes in Taiwanese.
OBJECTIVE Although hypomagnesemia reduces insulin sensitivity , benefits of magnesium supplementation to non-diabetic insulin resistant subjects has not been established . Our purpose was to determine whether oral magnesium supplementation with magnesium chloride ( MgCl2 ) 2.5 g daily modify insulin sensitivity in non-diabetic subjects . MATERIAL AND METHODS This study was a 3 months r and omized double-blind placebo-controlled trial . Apparently healthy subjects were eligible to participate if they had insulin resistance ( HOMA-IR index equal or greater than 3.0 ) and hypomagnesemia ( Serum magnesium levels equal or lower than 0.74 mmol/l ) . Subjects were r and omized to receive either , MgCl2 2.5 g daily or placebo by 3-months . RESULTS At baseline there were not significant anthropometric or laboratory differences between both groups . At ending of the study , magnesium-supplemented subjects significantly increased their serum magnesium levels ( 0.61 + /- 0.08 to 0.81 + /- 0.08 mmol/l , p<0.0001 ) and reduced HOMA-IR index ( 4.6 + /- 2.8 to 2.6 + /- 1.1 , p<0.0001 ) , whereas control subjects did not ( 0.62 + /- 0.08 to 0.61 + /- 0.08 mmol/l , p=0.063 and 5.2 + /- 1.9 to 5.3 + /- 2.9 , p=0.087 ) . CONCLUSIONS Oral magnesium supplementation improves insulin sensitivity in hypomagnesemic non-diabetic subjects . Clinical implication s of this finding have to be established Oral magnesium ( Mg ) supplementation can improve insulin sensitivity and secretion in patients with Type 2 diabetes mellitus ( DM ) . We studied the effect of Mg supplementation on glycaemic control , blood pressure , and plasma lipids in insulin-requiring patients with Type 2 DM . Fifty moderately controlled patients were r and omized to 15 mmol Mg or placebo daily for 3 months . Plasma Mg , glucose , HbA1c , lipids , erythrocyte Mg , Mg and glucose concentrations in 24-h urine , and systolic and diastolic pressure were measured before and after 3 months treatment . Plasma Mg concentration was higher after supplementation than after placebo ( 0.82 + /- 0.07 vs 0.78 + /- 0.08 mmol l(-1 ) , p < 0.05 ) , as was Mg excretion ( 5.5 + /- 1.9 vs 3.7 + /- 1.4 mmol 24 h(-1 ) , p = 0.004 ) but erythrocyte Mg concentrations were similar . No significant differences were found in glycaemic control ( glucose : 10.7 + /- 3.8 vs 11.6 + /- 6.2 mmol l(-1 ) , p = 0.8 ; HbA1c : 8.9 + /- 1.6 vs 9.1 + /- 1.2 % , p = 0.8 ) , lipids or blood pressure . On-treatment analysis ( 34 patients : 18 on Mg , 16 on placebo ) yielded similar results . An increase in plasma Mg concentration irrespective of medication was associated with a tendency to a decrease in diastolic pressure ( increased plasma Mg vs no increase : -4.0 + /- 10.1 vs + 2.5 + /- 12.0 mmHg , p = 0.059 ) . Three months ' oral Mg supplementation of insulin-requiring patients with Type 2 DM increased plasma Mg concentration and urinary Mg excretion but had no effect on glycaemic control or plasma lipid concentrations OBJECTIVE To evaluate the impact of oral magnesium supplementation on risk factors for end-organ disease in patients with non-insulin-dependent diabetes mellitus ( NIDDM ) . DESIGN A 16-week r and omized , double-blind , placebo-controlled crossover trial . SETTING Outpatient center of an academic family medicine residency program . PATIENTS Twenty-eight patients ( age range , 28 to 84 years ; 57.1 % black ; 85.7 % women ) with NIDDM controlled by diet and /or an oral hypoglycemic , with a serum cholesterol levels over 5.20 mmol/L ( 200 mg/dL ) . INTERVENTION Following a 2-week placebo run-in period , each patient was r and omized to receive either sustained-release magnesium chloride ( Slo-Mag ) , 384 mg/d , or an identical-appearing placebo for 6 weeks . After a 2-week interim washout period , each patient was then treated with the alternative regimen for an additional 6-week period . MAIN OUTCOME MEASURES The systolic and diastolic blood pressure and levels of serum glucose , low-density and high-density lipoprotein and total cholesterol , triglycerides , and serum and total erythrocyte magnesium were measured at the beginning , midpoint , and end of each 6-week treatment phase . RESULTS Systolic blood pressure fell an average of 7.4 mm Hg ( P < .05 ) with treatment . There was no significant change in diastolic blood pressure or levels of serum glucose , low-density and high-density lipoprotein and total cholesterol , triglycerides , or serum and erythrocyte magnesium . CONCLUSIONS Oral magnesium supplementation in the doses and duration studied is modestly effective in reducing systolic blood pressure in patients with NIDDM but has little impact on other important biochemical parameters related to diabetes-associated end-organ disease In eight aged non-insulin-dependent diabetes mellitus ( NIDDM ) subjects , insulin response and action were studied before and after chronic magnesium supplementation ( 2 g/day ) to diet . Chronic magnesium supplementation to diet versus placebo produced 7 ) a significant increase in plasma ( 0.83 ± 0.05 vs. 0.78 ± 0.06 mM , P < .05 ) and erythrocyte ( 2.03 ± 0.06 vs. 1.88 ± 0.09 mM , P < .01 ) magnesium levels , 2 ) an increase in acute insulin response ( AIR ) ( 4.0 ± 0.6 vs. - 1 .6 ± 0.6 mU/L , P < .05 ) to glucose pulse , and 3 ) an increase in glucose infusion rate ( GIR ) ( 3.6 ± 0.6 vs. 2.9 ± 0.5 mg kg∼1 min−1 P < .025 ) calculated in the last 60 min of a euglycemic-hyperinsulinemic ( 100U m2 · min−1 during 180 min ) glucose clamp . Net increase in AIR , glucose disappearance rate after glucose pulse , and GIR were significantly and positively correlated to the net increase in erythrocyte magnesium content calculated after chronic magnesium supplementation to diet . In conclusion , our data suggest that NIDDM subjects may benefit from therapeutic chronic administration of magnesium salts OBJECTIVE Hypomagnesemia occurs in 25–38 % of patients with type 2 diabetes . Several studies have suggested an association between magnesium ( Mg ) depletion and insulin resistance and /or reduction of insulin secretion in these cases . Our purpose was to evaluate if Mg supplementation ( as magnesium oxide [ MgO ] ) would improve metabolic control in patients with type 2 diabetes . RESEARCH DESIGN AND METHODS We studied 128 patients with type 2 diabetes ( 32 men , 96 women , aged 30–69 years ) , treated by diet or diet plus oral antidiabetic drugs , in the Bahia Federal University Hospital , Brazil . Patients at risk for hypomagnesemia or with reduced renal function were excluded . This study was a clinical r and omized double-blind placebo-controlled trial . Patients received either placebo , 20.7 mmol MgO , or 41.4 mmol MgO daily(elementary Mg ) for 30 days . Mg concentrations were measured in plasma , in mononuclear cells , and in 24-h urine sample s. Fasting blood glucose , HbA1 , and fructosamine were used as parameters of metabolic control . RESULTS Of the patients , 47.7 % had low plasma Mg , and 31.1 % had low intramononuclear Mg levels . Intracellular Mg in patients with diabetes was significantly lower than in the normal population ( 62 blood donors ; 1.4 ± 0.6 vs. 1.7 ± 0.6 μg/mg of total proteins ) . No correlation was found between plasma and intracellular Mg concentrations ( r = −0.179 ; P = 0.15 ) or between Mg concentrations and glycemic control ( r = −0.165 ; P = 0.12 ) . Intracellular Mg levels were lower in patients with peripheral neuropathy than in those without ( 1.2 ± 0.5 vs. 1.5 ± 0.6 μg/mg ) . Similar findings were observed in patients with coronary disease ( 1.0 ± 0.5 vs. 1.5 ± 0.6 μg/mg ) . In the placebo and in the 20.7 mmol Mg groups , neither a change in plasma and intracellular levels nor an improvement in glycemic control were observed . Replacement with 41.4 mmol Mg tended to increase plasma , cellular , and urine Mg and caused a significant fall ( 4.1 ± 0.8 to 3.8 ± 0.7 mmol/1 ) in fructosamine ( normal , 1.87–2.87 mmol/1 ) . CONCLUSIONS Mg depletion is common in poorly controlled patients with type 2 diabetes , especially in those with neuropathy or coronary disease . More prolonged use of Mg in doses that are higher than usual is needed toestablish its routine or selective administration in patients with type 2 diabetes to improve control or prevent chronic complications The aim of the present study was to investigate the effects of magnesium supplementation on glucose uptake and substrate oxidation in noninsulin-dependent ( type II ) diabetic patients . Nine elderly non-obese noninsulin-dependent ( type II ) diabetic patients , treated by diet only , participated in the study , which was design ed as r and omized , double blind , and cross-over . Each patient was followed up for a pre study period of 3 weeks before inviting him/her to receive placebo or magnesium supplementation ( 15.8 mmol/day ) for 4 weeks . At the end of each treatment period , a euglycemic hyperinsulinemic glucose clamp with simultaneous D-[3 - 3H]glucose infusion and indirect calorimetry was performed . Magnesium supplementation result ed in significantly increased plasma and erythrocyte magnesium levels , whereas body weight and fasting plasma glucose did not change . In the last 60 min of the glucose clamp , insulin-mediated glucose disappearance , total body glucose disposal ( 24.5 + /- 0.4 vs. 28.2 + /- 0.7 mumol/kg.min ; P < 0.005 ) , and glucose oxidation ( 13.0 + /- 0.4 vs. 16.3 + /- 0.8 mumol/kg.min ; P < 0.01 ) were increased after chronic magnesium supplementation . Endogenous glucose production , nonoxidative glucose disposal , lipid and protein oxidation , and insulin MCR were not affected . In conclusion , a 4-week magnesium supplementation improves insulin sensitivity and glucose oxidation in the course of a euglycemic-hyperinsulinemic glucose clamp in noninsulin-dependent diabetic patients . Long term studies are needed to determine whether magnesium supplementation is useful in the management of type II diabetes AIM This study evaluated the efficacy of oral magnesium supplementation in the reduction of plasma glucose levels in adults with prediabetes and hypomagnesaemia . METHODS A total of 116 men and non-pregnant women , aged 30 to 65 years with hypomagnesaemia and newly diagnosed with prediabetes , were enrolled into a r and omized double-blind placebo-controlled trial to receive either 30 mL of MgCl2 5 % solution ( equivalent to 382 mg of magnesium ) or an inert placebo solution once daily for four months . The primary trial endpoint was the efficacy of magnesium supplementation in reducing plasma glucose levels . RESULTS At baseline , there were no significant statistical differences in terms of anthropometric and biochemical variables between individuals in the supplement and placebo groups . At the end of follow-up , fasting ( 86.9 ± 7.9 and 98.3 ± 4.6 mg/dL , respectively ; P = 0.004 ) and post-load glucose ( 124.7 ± 33.4 and 136.7 ± 23.9 mg/dL , respectively ; P = 0.03 ) levels , HOMA-IR indices ( 2.85 ± 1.0 and 4.1 ± 2.7 , respectively ; P = 0.04 ) and triglycerides ( 166.4 ± 90.6 and 227.0 ± 89.7 , respectively ; P = 0.009 ) were significantly decreased , whereas HDL cholesterol ( 45.6 ± 10.9 and 46.8 ± 9.2 mg/dL , respectively ; P = 0.04 ) and serum magnesium ( 1.96 ± 0.27 and 1.60 ± 0.26 mg/dL , respectively ; P = 0.005 ) levels were significantly increased in those taking MgCl2 compared with the controls . A total of 34 ( 29.4 % ) people improved their glucose status ( 50.8 % and 7.0 % in the magnesium and placebo groups , respectively ; P < 0.0005 ) . CONCLUSION Our results show that magnesium supplementation reduces plasma glucose levels , and improves the glycaemic status of adults with prediabetes and hypomagnesaemia BACKGROUND AND AIM Little is known about the effect of magnesium on insulin sensitivity and BP in healthy individuals . Therefore , we investigated whether magnesium could improve insulin sensitivity and blood pressure ( BP ) in normo-magnesemic nondiabetic overweight adults . METHODS AND RESULTS In a double-blinded , placebo-controlled , r and omized trial , a total of 155 participants ( BMI > or = 23 kg/m(2 ) ) received either 12.3 mmol ( 300 mg ) of elemental magnesium in the form of magnesium oxide ( n=75 ) or placebo ( n=80 ) each day for 12 weeks , constituting the intent-to-treat population . A repeated- measures ANOVA was used to evaluate the between-group changes in variables during the study . The baseline characteristics between the intervention and control groups were similar . There were no significant differences between the groups in the pattern of change of the homeostasis model assessment insulin resistance index , BP over time during the 12-week study . In subgroup analysis , magnesium supplementation ( n=8 , 27 , and 24 , respectively ) lowered BP much more than placebo ( n=16 , 29 , and 25 , respectively ) in those subjects whose systolic BP > or = 140 mmHg , diastolic BP 80 - 90 mmHg , and diastolic BP > or = 90 mmHg at the start of the study ( P=0.016 , 0.043 , and 0.023 , respectively ) ; in comparison , those subjects whose initial BP reading was low at baseline did not show a change in BP . No significant adverse events related to magnesium supplementation were recorded . CONCLUSIONS These results suggested that magnesium supplementation does not reduce BP and enhance insulin sensitivity in normo-magnesemic nondiabetic overweight people . However , it appears that magnesium supplementation may lower BP in healthy adults with higher BP AIMS Early studies have shown that magnesium intake decreases the risk of Type 2 diabetes , but the results are still inconsistent . We prospect ively examined the association between magnesium intake and incidence of Type 2 diabetes in a general Japanese population . METHODS A total of 1999 subjects without diabetes aged 40 - 79 years who underwent a 75-g oral glucose tolerance test were followed up prospect ively for a mean of 15.6 years . RESULTS During the follow-up , 417 subjects developed Type 2 diabetes . The age- and sex-adjusted incidence of Type 2 diabetes significantly decreased with increasing magnesium intake quartile levels ( ≤ 148.5 , 148.6 - 171.5 , 171.6 - 195.5 and ≥ 195.6 mg/day , P for trend = 0.01 ) . In multivariate analyses , after adjusting for comprehensive risk factors and other dietary factors , the hazard ratio of Type 2 diabetes was 0.67 ( 95 % CI 0.49 - 0.92 ; P = 0.01 ) in the third quartile and 0.63 ( 95 % CI 0.44 - 0.90 ; P = 0.01 ) in the highest quartile compared with the first quartile . In addition , the risk of Type 2 diabetes was 14 % lower ( P = 0.04 ) for a 1-sd increment of log-transformed magnesium intake in the multivariate-adjusted model . In stratified analysis , there were statistically significant interactions  between magnesium intake and levels of homeostasis model assessment of insulin resistance , high-sensitivity C-reactive protein or alcohol intake on the risk of Type 2 diabetes ( all P < 0.05 ) . CONCLUSIONS Our findings suggest that increased magnesium  intake was a significant protective factor for the incidence of Type 2 diabetes  in the general Japanese population , especially among subjects with insulin resistance , low- grade inflammation and a drinking habit Background : Magnesium is the second most abundant intracellular cation . It plays an important role in insulin homeostasis and glucose metabolism through multiple enzymatic reactions . With increasing data on magnesium deficiency in diabetic patients and epidemiological studies demonstrating magnesium deficiency as a risk factor for diabetes , it is logical to search for its possible beneficial effects on diabetes control and prevention . We aim ed to determine whether oral magnesium supplementation improves metabolic control , lipid profile and blood pressure in patients with type II diabetes . Methods : Fifty four patients with type II diabetes were included in a r and omized double blind placebocontrolled clinical trial . Patients received either placebo or 300 mg elemental magnesium ( as magnesium sulfate -MgSo4- ) daily , for 3 months . Metabolic control , lipid profile , blood pressure , magnesium status , hepatic enzymes , hemoglobin concentration , and anthropometric indices were determined in the beginning and at the end of the study . Results : Daily administration of 300 mg elemental magnesium for 3 months , significantly improved fasting blood glucose ( 183.9±15.43 to 125.8±6.52 vs. 196.5±28.12 to 136.5±7.94 , p < 0.0001 ) , 2-hour post pr and ial glucose ( 239.1±74.75 to 189.1±60mg/dl vs. 246.4±97.37 to 247.8±86.74mg/dl , p < 0.01 ) , lipid profile , blood pressure and hepatic enzymes . Conclusion : Oral magnesium supplementation with proper dosage has beneficial effects on blood glucose , lipid profile , and blood pressure in patients with type II diabetes We evaluated the effects of oral magnesium supplementation on plasma lipid concentrations in patients with non-insulin-dependent diabetes mellitus . Twenty-six persons with non-insulin-dependent diabetes mellitus received 4.5 g magnesium pidolate/d for one month , and 17 persons received placebo . Before and at the end of the treatment period cholesterol concentration , triglycerides , LDL cholesterol , HDL cholesterol , and plasma and erythrocyte magnesium were evaluated . Chronic magnesium supplementation produced a significant reduction of plasma cholesterol and LDL cholesterol , and an increase of HDL cholesterol . These results suggest that oral supplementation of magnesium may be useful in the treatment of hyperlipidaemia in patients with non-insulin-dependent diabetes mellitus BACKGROUND Given that role of magnesium in insulin secretion is uncertain , our objective was to determine whether oral supplementation with magnesium chloride ( MgCl(2 ) ) improves the ability of beta-cells to compensate for variations in insulin sensitivity in non-diabetic individuals with significant hypomagnesaemia . MATERIAL S AND METHODS Eligible individuals were non-diabetic , normo-tensive men and non-diabetic , normo-tensive , non-pregnant women with serum magnesium levels ≤0·70 mM/L ; they were enrolled in a r and omized double-blind clinical trial to receive either 50 mL of 5 % MgCl(2 ) solution or 50 mL of inactive solution daily for 3 months . The primary trial end point was a change in the AUC of the hyperbolic model of beta-cell function ( HMbCF ) derived from the fasting state . Individuals , caregivers and personnel who assessed the outcomes were all blinded to the group assignments . RESULTS A total of 54 and 52 individuals were assigned to the MgCl(2 ) and placebo groups , respectively ; five individuals in the MgCl(2 ) group and four in the placebo group dropped out . There were no serious adverse events or side effects because of MgCl(2 ) or placebo . At the beginning of the study , the AUC of the HMbCF was similar in both groups ( AUC = 7·591 and 7·895 cm(2 ) ) ; at the end of follow-up , the curve of the MgCl(2 ) group showed a hyperbolic distribution ( AUC = 18·855 cm(2 ) ) , whereas in the placebo group , there were no changes ( AUC = 7·631 cm(2 ) ) . CONCLUSIONS MgCl(2 ) 2·5 g daily improves the ability of beta-cells to compensate for variations in insulin sensitivity in non-diabetic individuals with significant hypomagnesaemia BACKGROUND AND AIMS It has been suggested that magnesium deficiency is associated with the triggering of acute phase response , which may contribute to type 2 diabetes and cardiovascular disease risk . We undertook this study to determine whether oral magnesium supplementation modifies serum levels of high-sensitivity C-reactive protein ( hsCRP ) in apparently healthy subjects with prediabetes and hypomagnesemia . METHODS A total of 62 men and non-pregnant women aged 18 - 65 year , with new diagnosis of prediabetes ( glucose 5.6 < 7.0 mmol/L and /or post-load glucose ≥7.7 < 11.1 mmol/L ) and hypomagnesemia ( serum magnesium levels < 0.74 mmol/L ) were enrolled in a clinical double-blind placebo-controlled trial and r and omly allocated to receive either magnesium chloride ( 30 mL of MgCl2 5 % solution ) or NaHCO3 0.1 % solution , once daily for 3 months . RESULTS At basal conditions , anthropometric and biochemical variables were similarly distributed in both groups . At the end of follow-up , participants who received magnesium chloride showed higher serum magnesium levels ( 0.86 ± 0.08 vs. 0.69 ± 0.16 mmol/L , p = 0.002 ) and lower hsCRP levels ( 4.8 ± 15.2 vs. 17.1 ± 21.0 nmol/L , p = 0.01 ) compared with participants in the control group . CONCLUSIONS Oral magnesium supplementation decreases hsCRP levels in apparently healthy subjects with prediabetes and hypomagnesemia OBJECTIVE Higher intake of magnesium appears to improve glucose and insulin homeostasis ; however , there are sparse prospect i ve data on the association between magnesium intake and incidence of type 2 diabetes . RESEARCH DESIGN AND METHODS In the Women 's Health Study , a cohort of 39,345 U.S. women aged > /=45 years with no previous history of cardiovascular disease , cancer , or type 2 diabetes completed vali date d semiquantitative food frequency question naires in 1993 and were followed for an average of 6 years . We used Cox proportional hazard models to estimate multivariate relative risks ( RRs ) of type 2 diabetes across quintiles of magnesium intake compared with the lowest quintile . In a sample of 349 apparently healthy women from this study , we measured plasma fasting insulin levels to examine their relation to magnesium intake . RESULTS During 222,523 person-years of follow-up , we documented 918 confirmed incident cases of type 2 diabetes . There was a significant inverse association between  magnesium intake and risk of type 2 diabetes , independent of age and BMI ( P = 0.007 for trend ) . After further adjustment for physical activity , alcohol intake , smoking , family history of diabetes , and total calorie intake , the multivariate-adjusted RRs of diabetes from the lowest to highest quintiles of magnesium intake were attenuated at 1.0 , 1.06 , 0.81 , 0.86 , and 0.89 ( P = 0.05 for trend ) . Among women with BMI > /=25 kg/m2 , the inverse trend was significant ; multivariate-adjusted RRs were 1.0 , 0.96 , 0.76 , 0.84 , and 0.78 ( P = 0.02 for trend ) . Multivariate-adjusted geometric mean insulin levels for overweight women in the lowest quartile of magnesium intake was 53.5 compared with 41.5 pmol/l among those at the highest quartile ( P = 0.03 for trend ) . CONCLUSIONS These findings support a protective role of higher intake of magnesium in reducing the risk of developing type 2 diabetes , especially in overweight women We demonstrated similar plasma concentrations and urinary losses but lower erythrocyte magnesium concentrations ( 2.18 + /- 0.04 vs 1.86 + /- 0.03 mmol/L , P less than 0.01 ) in twelve aged ( 77.8 + /- 2.1 y ) vs 25 young ( 36.1 + /- 0.4 y ) , nonobese subjects . Subsequently , aged subjects were enrolled in a double-blind , r and omized , crossover study in which placebo ( for 4 wk ) and chronic magnesium administration ( CMA ) ( 4.5 g/d for 4 wk ) were provided . At the end of each treatment period an intravenous glucose tolerance test ( 0.33 g/kg body wt ) and a euglycemic glucose clamp with simultaneous [D-3H]glucose infusion and indirect calorimetry were performed . CMA vs placebo significantly increased erythrocyte magnesium concentration and improved insulin response and action . Net increase in erythrocyte magnesium significantly and positively correlated with the decrease in erythrocyte membrane microviscosity and with the net increase in both insulin secretion and action . In aged patients , correction of a low erythrocyte magnesium concentration may allow an improvement of glucose h and ling The effect of magnesium ( Mg ) and ascorbic acid ( AA ) supplementation on metabolic control was assessed in 56 outpatient diabetics . A 90-day run-in period was followed by two 90-day treatment periods , during which Mg ( 600 mg/day ) and AA ( 2 g/day ) were administered in a r and omized double-blind cross-over fashion . A decrease in systolic and diastolic blood pressure ( 132 + /- 3 vs. 138 + /- 4 and 77 + /- 2 vs. 82 + /- 2 mm Hg ; p < 0.05 ) was observed in insulin-dependent diabetes mellitus subjects during Mg supplementation . No beneficial effect of Mg supplementation was observed on glycemic control , lipids or blood pressure in non-insulin-dependent diabetes mellitus ( NIDDM ) subjects . AA supplementation improved glycemic control among NIDDM subjects and both fasting blood glucose ( 9.1 + /- 0.5 vs. 10.1 + /- 0.6 mmol/l ; p < 0.05 ) and HbA1c ( 8.5 + /- 0.3 vs. 9.3 + /- 0.3 % ; p < 0.05 ) improved . Beneficial effects of AA supplementation on cholesterol ( 5.9 + /- 0.2 vs. 6.2 + /- 0.2 mmol/l ; p < 0.05 ) and triglycerides ( 2.2 + /- 0.2 vs. 2.5 + /- 0.2 ; p < 0.05 ) were also observed in NIDDM subjects . The results suggest that high-dose AA supplementation may have a beneficial effect in NIDDM subjects on both glycemic control and blood lipids BACKGROUND / PURPOSE Several studies have indicated an inverse association between the incidence of diabetes mellitus and magnesium and dietary fiber intake . Few studies have examined both of these associations together , not to mention in Asian population s with prospect i ve study design . We therefore aim ed to study how dietary magnesium and fiber intake levels affect diabetes incidence separately or in combination , in a prospect i ve study in Taiwan . METHODS The study subjects were recruited for a longitudinal study , CardioVascular Disease risk FACtor Two-township Study cycle 2 from November 1990 . Data from complete baseline information on dietary and biochemical profile and at least one additional follow-up visit were gathered on a total of 1604 healthy subjects aged 30 years and over . Cox proportional hazard model was used to study the association between diabetes incidence and dietary magnesium and fiber intake level estimated from a food frequency question naire . RESULTS A total of 141 diabetes mellitus events were identified and confirmed during the 4.6 years of follow-up ( 7365.1 person-years ) . A significantly higher diabetes risk was observed for people in the lowest quintile of total dietary fiber intake ( hazard ratio = 2.04 ; 95 % CI = 1.17 - 3.53 ) and magnesium intake ( hazard ratio = 2.61 ; 95 % CI = 1.42 - 4.79 ) compared with the highest quintile after adjusting for traditional cardiovascular disease risk factors . Similar inverse associations for total dietary fiber were also shown for vegetable fiber and fruit fiber . CONCLUSION Lower magnesium , lower total dietary fiber intake , or lower intake of both was associated with higher risk of diabetes in the Taiwanese population . Clinical trials are required to confirm the protective effects of the adequate intake of fiber , magnesium , and /or their combination
Mg supplementation appears to have a beneficial role and improves glucose parameters in people with diabetes and also improves insulin-sensitivity parameters in those at high risk of diabetes
Although higher dietary intakes of magnesium ( Mg ) seem to correspond to lower diabetes incidence , research concerning Mg supplementation in people with or at risk of diabetes is limited .
Thus , we aim ed to investigate the effect of oral Mg supplementation on glucose and insulin-sensitivity parameters in participants with diabetes or at high risk of diabetes compared with placebo .